Kayentis Clin’form eCOA and eConsent

Kayentis is a provider of electronic clinical outcome assessment (eCOA) and decentralized clinical trial solutions, with offices in Meylan, France and Boston, United States and operations across the US, Europe and Asia. The site says it has served pharma, biotech and CRO clients since 2005, but does not give a founding year.

The Clin'form platform covers eCOA, eConsent, patient engagement modules, televisits and connections to external systems such as IRT, digital health technologies, patient portals and clinical data lakes. Studies can run on-site or at home, and an AI builder converts PDF consent forms into multimedia eConsent.

• eCOA: electronic outcome assessments completed on-site or at home.
• eConsent: multimedia consent with videos, glossary and comprehension questions.
• AI consent builder: converts PDF consent forms into interactive eConsent.
• Televisit: remote visits embedded in the platform.
• Integrations: connects to IRT, wearables and digital health technologies, patient portals and data lakes.
• Wearable adherence: Ametris partnership adds adherence monitoring to the Clin'form App.

Vietnamese CROs and hospital research units could deploy eConsent with translated multimedia materials for global trials. Oncology and neurology studies could use at-home eCOA with wearable adherence tracking to reduce site visits.

Supports both on-site and at-home data collection in one platform. Shortens eConsent setup through an AI builder. Gives sites a single login for consent and data collection. Consent records are stated to be 21 CFR Part 11 compliant. Covers more than 20 therapeutic areas.

Sponsors increasingly combine eCOA, eConsent and wearable data to run hybrid and decentralized studies. Asia-Pacific is a growing trial region, and Vietnamese sites joining global studies need localized, compliant electronic consent and outcome tools.

Operating since 2005 per the website (no founding year stated). Offices in Meylan, France and Boston, USA. CEO Guillaume Juge. 2025-09: reported 40% rise in orders and appointed a Chief Commercial Officer.